GlassScriptPhysician profile
Brian C Taschner
NPI 1538126966
$7,221.28
in general payments reported to CMS, 2019-2025
34 companies · $176 in 2025
The $176 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,621 · 2020: $652 · 2021: $1,022 · 2022: $1,612 · 2023: $1,616 · 2024: $521 · 2025: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,314.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,313.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $842.45 | 2019-2023 | Xarelto |
| Amgen INC. | $834.04 | 2019-2023 | Repatha |
| Novartis Pharmaceuticals Corporation | $767.94 | 2019-2025 | |
| Pfizer INC. | $459.55 | 2022-2025 | |
| Kestra Medical Technology Services, INC. | $425.67 | 2023-2024 | Assure Wcd |
| Sanofi-Aventis U.S. LLC | $390.91 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $376.27 | 2019-2023 | Evkeeza, Praluent |
| Astrazeneca Pharmaceuticals LP | $346.02 | 2019-2025 | Farxiga, Brilinta |
| Amarin Pharma, INC. | $310.19 | 2019-2022 | |
| Philips North America LLC | $297.43 | 2023-2025 | (5091) Amb Mon & Diag Und, (Cm9) Amb Mon & Diag Und, Extended Holter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $289.41 | 2019-2024 | Jardiance |
| Boston Scientific Corporation | $227.12 | 2020-2022 | |
| Haemonetics Corporation | $218.38 | 2020 | |
| Astellas Pharma US INC | $183.30 | 2019 | |
| Merck Sharp & Dohme LLC | $179.47 | 2023-2025 | Verquvo |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $178.89 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $165.61 | 2019-2023 | Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $86.33 | 2023 | |
| Medtronic Vascular, INC. | $82.58 | 2019-2020 | |
| Impulse Dynamics (USA) INC. | $66.10 | 2024 | Optimizer |
| Cvrx, INC. | $63.76 | 2023-2025 | Barostim Neo System |
| Medtronic, INC. | $60.23 | 2021-2024 | Linq II |
| Lexicon Pharmaceuticals, INC. | $57.23 | 2023 | Inpefa |
| Heartflow, INC. | $47.68 | 2023 | Ffrct |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $44.81 | 2019-2023 | Lifevest |
| Esperion Therapeutics, INC. | $37.85 | 2022-2025 | Nexletol |
| Abbott Laboratories | $35.96 | 2021 | |
| Novo Nordisk INC | $28.49 | 2025 | Wegovy |
| Alnylam Pharmaceuticals INC. | $27.40 | 2023 | Onpattro |
| Artivion, INC. | $25.77 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $18.94 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $17.56 | 2023 | Arcalyst |
| Preventice Services, LLC | $14.80 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $13.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Taschner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.